Wedbush Maintains Neutral on Ultragenyx Pharmaceutical, Raises Price Target to $51
Portfolio Pulse from richadhand@benzinga.com
Wedbush analyst Laura Chico maintains a Neutral rating on Ultragenyx Pharmaceutical (NASDAQ:RARE) and raises the price target from $48 to $51.
June 06, 2023 | 11:47 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Wedbush analyst Laura Chico maintains a Neutral rating on Ultragenyx Pharmaceutical and raises the price target from $48 to $51.
The news directly mentions Ultragenyx Pharmaceutical (RARE) and the price target increase by Wedbush analyst Laura Chico. However, the Neutral rating remains unchanged, which indicates that the stock price may not experience significant short-term movement based on this news alone.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100